MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 ...
Zacks Small Cap Research on MSN

MTVA: Phase 1 part 3 16-week titration study of DA-1726 to initiate in April 2026

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to Initiate in April 2026 On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced ...

MetaVia Inc.: MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ ...